CN1264847C - 1-氧杂-3,9-二氮杂-螺[5.5]十一-2-酮衍生物及其作为神经激肽受体拮抗剂的用途 - Google Patents
1-氧杂-3,9-二氮杂-螺[5.5]十一-2-酮衍生物及其作为神经激肽受体拮抗剂的用途 Download PDFInfo
- Publication number
- CN1264847C CN1264847C CNB028094735A CN02809473A CN1264847C CN 1264847 C CN1264847 C CN 1264847C CN B028094735 A CNB028094735 A CN B028094735A CN 02809473 A CN02809473 A CN 02809473A CN 1264847 C CN1264847 C CN 1264847C
- Authority
- CN
- China
- Prior art keywords
- spiro
- oxa
- bis
- trifluoromethyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01111644 | 2001-05-14 | ||
| EP01111644.9 | 2001-05-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1507449A CN1507449A (zh) | 2004-06-23 |
| CN1264847C true CN1264847C (zh) | 2006-07-19 |
Family
ID=8177412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028094735A Expired - Fee Related CN1264847C (zh) | 2001-05-14 | 2002-05-06 | 1-氧杂-3,9-二氮杂-螺[5.5]十一-2-酮衍生物及其作为神经激肽受体拮抗剂的用途 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6599900B2 (https=) |
| EP (1) | EP1390372B1 (https=) |
| JP (1) | JP4056887B2 (https=) |
| KR (1) | KR100618063B1 (https=) |
| CN (1) | CN1264847C (https=) |
| AR (1) | AR033631A1 (https=) |
| AT (1) | ATE401333T1 (https=) |
| AU (1) | AU2002342238B2 (https=) |
| BR (1) | BR0209604A (https=) |
| CA (1) | CA2447329C (https=) |
| DE (1) | DE60227657D1 (https=) |
| DK (1) | DK1390372T3 (https=) |
| ES (1) | ES2310206T3 (https=) |
| MX (1) | MXPA03010321A (https=) |
| PT (1) | PT1390372E (https=) |
| WO (1) | WO2002092604A1 (https=) |
| ZA (1) | ZA200308535B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100863854B1 (ko) | 2004-02-10 | 2008-10-15 | 에프. 호프만-라 로슈 아게 | 케모카인 ccr5 수용체 조절제 |
| JP2008531509A (ja) | 2005-02-25 | 2008-08-14 | エフ.ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| KR101355064B1 (ko) * | 2005-03-03 | 2014-01-24 | 얀센 파마슈티카 엔.브이. | 치환된 옥사-디아자-스피로-[5.5]-운데카논 유도체 및뉴로키닌 길항제로서의 이의 용도 |
| ATE478075T1 (de) | 2005-03-08 | 2010-09-15 | Janssen Pharmaceutica Nv | Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten |
| US7470684B2 (en) * | 2007-01-03 | 2008-12-30 | Hoffmann-La Roche Inc. | Spiropiperidine derivatives as NK3 antagonists |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| JP2010522707A (ja) | 2007-03-29 | 2010-07-08 | エフ.ホフマン−ラ ロシュ アーゲー | 抗ウイルス性複素環化合物 |
| TN2017000544A1 (en) | 2015-07-31 | 2019-04-12 | Pfizer | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| RU2720203C1 (ru) | 2017-01-20 | 2020-04-27 | Пфайзер Инк. | 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl |
| CN110198944A (zh) | 2017-01-23 | 2019-09-03 | 辉瑞大药厂 | 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物 |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2131021B (en) * | 1982-11-24 | 1985-12-18 | Erba Farmitalia | Antipsychotic benzoxazines |
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| DE69633245T2 (de) * | 1995-09-29 | 2005-09-08 | Eli Lilly And Co., Indianapolis | Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation |
-
2002
- 2002-05-06 CN CNB028094735A patent/CN1264847C/zh not_active Expired - Fee Related
- 2002-05-06 ES ES02742943T patent/ES2310206T3/es not_active Expired - Lifetime
- 2002-05-06 EP EP02742943A patent/EP1390372B1/en not_active Expired - Lifetime
- 2002-05-06 CA CA002447329A patent/CA2447329C/en not_active Expired - Fee Related
- 2002-05-06 AU AU2002342238A patent/AU2002342238B2/en not_active Ceased
- 2002-05-06 WO PCT/EP2002/004935 patent/WO2002092604A1/en not_active Ceased
- 2002-05-06 KR KR1020037014713A patent/KR100618063B1/ko not_active Expired - Fee Related
- 2002-05-06 JP JP2002589488A patent/JP4056887B2/ja not_active Expired - Fee Related
- 2002-05-06 AT AT02742943T patent/ATE401333T1/de not_active IP Right Cessation
- 2002-05-06 PT PT02742943T patent/PT1390372E/pt unknown
- 2002-05-06 DK DK02742943T patent/DK1390372T3/da active
- 2002-05-06 MX MXPA03010321A patent/MXPA03010321A/es active IP Right Grant
- 2002-05-06 BR BR0209604-8A patent/BR0209604A/pt not_active IP Right Cessation
- 2002-05-06 DE DE60227657T patent/DE60227657D1/de not_active Expired - Lifetime
- 2002-05-10 US US10/143,431 patent/US6599900B2/en not_active Expired - Fee Related
- 2002-05-10 AR ARP020101705A patent/AR033631A1/es unknown
-
2003
- 2003-10-31 ZA ZA200308535A patent/ZA200308535B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1507449A (zh) | 2004-06-23 |
| CA2447329C (en) | 2009-07-28 |
| AU2002342238B2 (en) | 2007-01-25 |
| BR0209604A (pt) | 2004-03-23 |
| KR20030094405A (ko) | 2003-12-11 |
| MXPA03010321A (es) | 2004-02-17 |
| AR033631A1 (es) | 2003-12-26 |
| KR100618063B1 (ko) | 2006-08-30 |
| WO2002092604A1 (en) | 2002-11-21 |
| ZA200308535B (en) | 2005-01-31 |
| DK1390372T3 (da) | 2008-09-15 |
| JP2004534758A (ja) | 2004-11-18 |
| DE60227657D1 (de) | 2008-08-28 |
| EP1390372B1 (en) | 2008-07-16 |
| ES2310206T3 (es) | 2009-01-01 |
| EP1390372A1 (en) | 2004-02-25 |
| PT1390372E (pt) | 2008-08-25 |
| JP4056887B2 (ja) | 2008-03-05 |
| ATE401333T1 (de) | 2008-08-15 |
| US20030004163A1 (en) | 2003-01-02 |
| US6599900B2 (en) | 2003-07-29 |
| CA2447329A1 (en) | 2002-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1247588C (zh) | 腺苷A2a受体拮抗剂 | |
| CN100351236C (zh) | 用作5-羟色胺-6配体的1-杂环基烷基-3-磺酰基-吲哚衍生物,其制备方法和用途 | |
| CN1281605C (zh) | 作为5-羟色胺-6配基的杂环基-吲唑或氮杂吲唑化合物 | |
| CN1092643C (zh) | 用于增强记忆的氨甲基苯基咪唑衍生物 | |
| CN1231467C (zh) | 伤害感受蛋白受体orl-1的高亲合性配体,包含它们的药物组合物以及它们的用途 | |
| CN1192032C (zh) | 用作神经激肽-1受体拮抗剂的4-苯基-吡啶衍生物 | |
| CN1264847C (zh) | 1-氧杂-3,9-二氮杂-螺[5.5]十一-2-酮衍生物及其作为神经激肽受体拮抗剂的用途 | |
| CN1150165C (zh) | 用于治疗中枢神经系统紊乱的1-芳基磺酰基-2-芳基-吡咯烷衍生物 | |
| CN1602196A (zh) | 作为腺苷调节剂的2-氨基苯并噻唑脲 | |
| CN1229373C (zh) | 作为神经激肽1拮抗剂的哌啶衍生物 | |
| CN1202169A (zh) | 作为5-ht4或h3受体配位体有效的5-苯基-3-(哌啶-4-基)-1,3,4-噁二唑-2(3h)-酮衍生物 | |
| CN1688581A (zh) | [1,2,4]-三唑二环腺苷A2a受体拮抗剂 | |
| CN1492863A (zh) | 作为5-羟色胺-6配基的杂环基烷基-吲哚或氮杂吲哚化合物 | |
| CN1468224A (zh) | 用作α-2拮抗剂的喹啉衍生物 | |
| CN1946723A (zh) | 取代的二氮杂-螺-[4.5]-癸烷衍生物及其作为神经激肽拮抗剂的应用 | |
| CN1198817C (zh) | 作为组胺-h3激动剂或拮抗剂的n-(咪唑基烷基)取代的环胺 | |
| CN1756740A (zh) | 具有2,6-二取代苯乙烯基的含氮杂环衍生物 | |
| CN1662544A (zh) | 对血清素受体具有亲和力、可用作治疗剂的新型四环芳基磺酰吲哚、其制备方法及其药物组合物 | |
| CN1030753A (zh) | 制备新的取代n-(3-羟基-4-哌啶基)苯甲酰胺的方法 | |
| CN1178923C (zh) | 1,4-二氮杂环庚烷-2,5-二酮衍生物及其作为nk-1受体拮抗剂的应用 | |
| CN1274675C (zh) | 环丁烯二酮化合物及其制备方法和含这些化合物的药物组合物 | |
| CN101035533A (zh) | 抗精神分裂症的双重nk1/nk3拮抗剂 | |
| CN1272842A (zh) | 作为速激肽受体拮抗剂的2-酰氨基丙胺类化合物 | |
| CN1249059C (zh) | 新型哌啶羧酸酰胺衍生物、其制备方法以及含有它们的药物组合物 | |
| CN1875016A (zh) | 咪唑衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060719 Termination date: 20110506 |